[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L, Chen L, Shen ZX, Lu H, Zhao WL, Janin A: Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol; 2010;3:30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
  • Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor.
  • However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
  • In this case, lymph node biopsies were performed before and six months after temsirolimus therapy.
  • Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
  • Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
  • Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Sirolimus / analogs & derivatives. TOR Serine-Threonine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Br J Haematol. 2004 Jan;124(2):130-40 [14687022.001]
  • [Cites] Am J Pathol. 1977 Apr;87(1):143-58 [851163.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4463-9 [15671443.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Leukemia. 2010 Jan;24(1):13-21 [19865108.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3509-12 [17179228.001]
  • [Cites] Blood. 2008 May 15;111(10):5142-51 [18339899.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1469-76 [19556426.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5549-54 [16740688.001]
  • (PMID = 20828385.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2944815
  •  go-up   go-down


2. Kella VK, Constantine R, Parikh NS, Reed M, Cosgrove JM, Abo SM, King S: Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature. World J Surg Oncol; 2009;7:60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature.
  • BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node.
  • Few cases of mantle cell lymphoma presenting with intussuception have been reported.
  • Here we present a rare case of multiple intussusceptions caused by mantle cell lymphoma and review the literature of this disease.
  • The histology and immuno-histochemistry of the excised small and large bowel revealed mantle cell lymphoma with multiple lymphomatous polyposis and positivity to Cyclin D1 marker.
  • The patient was successfully treated with Rituximab-CHOP chemotherapy and remains in complete remission at one-year follow-up.
  • CONCLUSION: This is a rare case of intestinal lymphomatous polyposis due to mantle cell lymphoma presenting with multiple small bowel intussusceptions.
  • Our case highlights laparoscopic-assisted bowel resection as a potential and feasible option in the multi-disciplinary treatment of mantle cell lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / complications. Ileal Diseases / etiology. Intussusception / etiology. Lymphoma, Mantle-Cell / complications


3. Hatzibougias D, Bobos M, Karayannopoulou G, Karkavelas G, Karapanagiotidis GT, Foroulis CN, Kostopoulos I: A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World J Surg Oncol; 2008;6:137
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura.
  • BACKGROUND: Coexistence of adenocarcinoma and mantle cell lymphoma in the same or different anatomical sites is extremely rare.
  • We present a case of incidental discovery of primary lung adenocarcinoma and mantle cell lymphoma involving the pleura, during an axillary thoracotomy performed for a benign condition.
  • Histologic examination of the stripped-off parietal pleura and of the bullectomy specimen revealed the synchronous occurrence of two distinct neoplasms, a lymphoma infiltrating the pleura and a primary, early lung adenocarcinoma.
  • The morphologic, immunophenotypic and genetic findings supported the diagnosis of primary lung adenocarcinoma (papillary subtype) coexisting with a non-Hodgkin, B-cell lineage, mantle cell lymphoma involving both, visceral and parietal pleura and without mediastinal lymph node involvement.
  • The neoplastic lymphoid cells showed the characteristic immunophenotype of mantle cell lymphoma and the translocation t(11;14).
  • The patient received 6 cycles of chemotherapy, while pulmonary function tests precluded further pulmonary parenchyma resection (lobectomy) for his adenocarcinoma.
  • CONCLUSION: This is the first reported case of a rare tumoral combination involving simultaneously lung and pleura, emphasizing at the incidental discovery of the two coexisting neoplasms during a procedure performed for a benign condition.
  • Any tissue specimen resected during operations performed for non-tumoral conditions should be routinely sent for pathologic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jan;32(1):129-32 [11172307.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):811-7 [11504842.001]
  • [Cites] Thorac Cardiovasc Surg. 2002 Feb;50(1):59-61 [11847607.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):141-8 [11902564.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E64-6 [12562254.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):409-14 [15101734.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):625-31 [6378757.001]
  • [Cites] Histopathology. 1995 Jan;26(1):17-24 [7713480.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2715-23 [7670110.001]
  • [Cites] Postgrad Med J. 1995 Jul;71(837):443 [7567744.001]
  • [Cites] An Med Interna. 2006 Jun;23(6):301-2 [17078163.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1497-502 [17090191.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):638-47 [17431413.001]
  • (PMID = 19114021.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2629472
  •  go-up   go-down


Advertisement
4. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R: Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res; 2005 Jan 15;65(2):587-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with poor response to therapy and unfavorable prognosis.
  • Here, we show that retinoic acid (RA) isomers significantly inhibit the proliferation of both primary MCL cultures (n = 7) and established cell lines (Granta 519 and SP-53) as shown by [(3)H]thymidine uptake and carboxyfluorescein diacetate succinimidyl ester labeling coupled with cyclin D1 staining.
  • RA induces cell accumulation in G(0)-G(1) together with a marked up-regulation of p27(Kip1) by inhibiting ubiquitination and proteasome-dependent degradation of the protein.
  • Experiments with receptor-selective ligands indicate that RA receptor alpha cooperates with retinoid X receptors in mediating RA-dependent MCL cell growth inhibition.
  • Immunohistochemical analysis showed that significant numbers of CD40L-expressing lymphoid cells are present in lymph node biopsies of MCL patients.
  • [MeSH-major] Antigens, CD40 / pharmacology. Interleukin-4 / pharmacology. Lymphoma, Mantle-Cell / drug therapy. Tretinoin / pharmacology
  • [MeSH-minor] Aged. CD40 Ligand / biosynthesis. Cell Cycle Proteins / metabolism. Cell Proliferation / drug effects. Cell Survival / drug effects. Cyclin D1 / metabolism. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Female. Humans. Male. Middle Aged. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors. Proto-Oncogene Proteins / metabolism. Receptors, Retinoic Acid / physiology. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695403.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147205-72-9 / CD40 Ligand; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 207137-56-2 / Interleukin-4; 5688UTC01R / Tretinoin; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


5. Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, Tiemann M, Dreger P, Kneba M: Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol; 2005 Apr;74(4):353-8
Genetic Alliance. consumer health - Mantle cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
  • OBJECTIVES: Classical mantle cell lymphoma (MCL) and its blastoid variant (MCL-BV) are characterized by an extremely poor prognosis.
  • Long-time survivors are rare, only very few patients with an overall survival over 10 years have been reported.
  • We present a case of a 41-year-old male with a 12 yr history of MCL stage I to show, that very late relapses in MCL are possible and may present as a transformation into an aggressive blastoid variant and to illustrate the value of quantitative minimal residual disease (MRD) monitoring for treatment guidance.
  • METHODS: Diagnostic lymph node and bone marrow samples were investigated by immunohistochemistry.
  • The MRD assessment was done by real-time quantitative PCR (RQ-PCR) on available follow-up samples.
  • Quantitative MRD assessment revealed significant MRD levels after intensive conventional chemotherapy including Rituximab.
  • Therefore, treatment was early intensified by myeloablative radio-chemotherapy and allogeneic peripheral stem cell transplantation from an unrelated HLA-identical donor.
  • CONCLUSION: This report presents a rare case of long-term survivor of MCL with a progression of the original MCL cell clone to MCL-BV and demonstrates the clinical value of quantitative MRD assessment for optimized therapeutic management.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Base Sequence. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. DNA, Neoplasm / genetics. Fatal Outcome. Genes, Immunoglobulin. Humans. Male. Peripheral Blood Stem Cell Transplantation. Time Factors. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • (PMID = 15777349.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


6. Kikuchi T, Asano N, Noguchi T, Nomura E, Uchimi K, Kagaya H, Suzuki S, Suzuki M, Kayaba Y, Tateno H, Onodera H: [A case of primary gastric mantle cell lymphoma]. Nihon Shokakibyo Gakkai Zasshi; 2009 Aug;106(8):1168-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary gastric mantle cell lymphoma].
  • After 6 months, erosions also formed in the duodenal bulb and systemic lymph nodes become enlarged.
  • After 20 months, the gastroduodenal erosions developed into mucosal ulcers, and the systemic lymph node swelling progressed.
  • Histological examination of the neck lymph node showed mantle cell lymphoma (MCL).
  • This case was diagnosed as recurrent primary gastric MCL in other areas, with systemic lymph node metastasis and bone marrow invasion.
  • Hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone), high-dose methotrexate and cytarabine in combination with Rituximab and stem cell transplantation was performed.
  • The gastroduodenal lesions and atypical cells in the bone marrow disappeared after 2 cycles of the chemotherapy.
  • Metastatic lymph node swelling regressed after stem cell transplantation.
  • Primary gastric MCL is very rare and cyclin D1 immunohistochemistry and FISH assay were very useful for the diagnosis of MCL.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged


7. Iranzo P, López I, Robles MT, Mascaró JM Jr, Campo E, Herrero C: Bullous pemphigoid associated with mantle cell lymphoma. Arch Dermatol; 2004 Dec;140(12):1496-9
MedlinePlus Health Information. consumer health - Pemphigus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bullous pemphigoid associated with mantle cell lymphoma.
  • BACKGROUND: Bullous pemphigoid has developed in association with different types of malignant diseases, including a few cases of B-cell lymphoproliferative disorders.
  • The results of histologic, immunofluorescence, and antigenic studies confirmed the diagnosis of bullous pemphigoid.
  • The histopathologic and immunophenotypic features of a lymph node biopsy specimen were consistent with mantle cell lymphoma.
  • There was total resolution of the mucocutaneous lesions when mantle cell lymphoma went into remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / complications. Lymphoma, Mantle-Cell / drug therapy. Paraneoplastic Syndromes / etiology. Pemphigoid, Bullous / etiology
  • [MeSH-minor] Adult. Biopsy. Humans. Lymph Nodes / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Bullous Pemphigoid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611428.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, Klapper W, European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood; 2008 Feb 15;111(4):2385-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
  • Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous.
  • Tumor cell proliferation as assessed by the Ki-67 index has been shown to yield prognostic information on MCL in many studies using heterogeneously treated patient cohorts.
  • The prognostic value of the Ki-67 index in patients treated with anti-CD20 therapy has not been studied so far.
  • We analyzed the Ki-67 index at primary diagnosis in 249 advanced-stage MCL patients treated within randomized trials.
  • The 3 groups with different Ki-67 index of less than 10%, 10% to less than 30%, and 30% or more showed significantly different overall survival in patients treated with CHOP (P = .001) as well as in patients treated with CHOP in combination with anti-CD20 therapy (R-CHOP, P = .013).
  • Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy.
  • [MeSH-major] Antigens, CD20 / immunology. Ki-67 Antigen / blood. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Biomarkers / blood. Europe. Germany. Humans. Immunotherapy. Multicenter Studies as Topic. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077791.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00016887
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers; 0 / Ki-67 Antigen
  • [Investigator] Nitsche M; Weikersthal; Hahn M; Gensicke D; Schlimok S; Langer M; Possinger S; Ludwig M; Weh A; Rhode E; Dietrich KB; Schmiegel G; Musch R; Wörmann J; Pflüger D; Hänel N; Peter CT; Heike; Lange; Haas; Rösler; Fuchs WI; Dührsen N; Heit W; Saal H; Reiber S; Mertelsmann F; Fassbinder H; Heil S; Schliesser; Trümper G; Eimermacher L; Kraus H; Schmoll W; Spohn M; Hurtz R; Schmitz N; Zander K; Bokemeyer; Walter; Schmidt; Henne; Dietzfelbinger; Basler S; Pfreundschuh; Gasiorek; Höffken F; Bentz W; Mezger G; Mosthaf ZB; Siehl S; Löser US; Kneba; Eisenhauer N; Helmer N; Hallek R; Fokken; Aldaoud S; Mantovani M; Baumgarten; Heidenreich J; Liebau N; Uppenkamp H; Fetscher S; Heil TL; Franke JU; Kettner K; Huber F; Hehlmann L; Neubauer S; Bodenstein W; Becker KB; Götz J; Graeven K; Lunscken; Forstpointner D; Hentrich S; Abenhardt T; Berdel; Wehmeyer L; Ladda; Nürnberg; Heuser; Ehscheidt J; Wilhelm W; Böck B; Henning-Köhne M; Otremba Z; Wolff N; Theilmann S; Gmelin; Maschmeyer R; Kautzsch R; Andreesen K; Kreuser; Neeck KS; Freund; Hähling S; Seitz K; Mergenthaler S; Aulitzky M; Höring E; Heidemann K; Fiechtner; Biedermann K; Kölbel W; Clemens; Forstbauer A; Reiter; Brettner B; Vedder R; Katz M; Bock; Sandmann B; Einsele W; Schlag; Kreibich
  •  go-up   go-down


9. Hara S, Yokote T, Akioka T, Oka S, Yamano T, Tsuji M, Hanafusa T: [Successful treatment of refractory mantle cell lymphoma with irinotecan]. Rinsho Ketsueki; 2005 May;46(5):358-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of refractory mantle cell lymphoma with irinotecan].
  • An inguinal lymph node biopsy showed mantle cell lymphoma (MCL).
  • After four courses of Rituximab-CHOP therapy were administered, complete response (CR) was achieved.
  • Several salvage therapies (ESHAP, Hyper-CVAD/MTX-ara-C) were administered, but CR was not achieved.
  • After two courses of single-agent chemotherapy with CPT-11 (40 mg/m2) were administered on days 1, 2, 3, 8, 9, and 10, CR was achieved.
  • Several studies reveal that the long-term prognosis for MCL with conventional therapy is poor.
  • This report describes CPT-11 therapy for MCL and provides evidence that CPT-11 is another therapeutic option in refractory cases of MCL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Male. Middle Aged. Remission Induction. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444969.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 16
  •  go-up   go-down


10. Yoneda S, Yoshiji H, Kuriyama S, Kojima H, Houki N, Matsumoto S, Nakajima Y, Tsutsumi M, Fukui H: Stage I mantle-cell lymphoma that was difficult to differentiate from abdominal tuberculous lymphadenitis and metastatic pancreatic cancer. J Gastroenterol; 2002;37(10):859-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I mantle-cell lymphoma that was difficult to differentiate from abdominal tuberculous lymphadenitis and metastatic pancreatic cancer.
  • Abdominal ultrasonography and enhanced computed tomography scanning revealed many enlarged lymph nodes, mainly around the pancreas tail and the hilus of the spleen.
  • Because we could not reach a final diagnosis, an exploratory laparotomy was performed.
  • Histopathological examination revealed mantle-cell lymphoma.
  • After chemotherapy combined with radiotherapy, the lymph-node swelling had disappeared.
  • Herein, we report this case of stage-I mantle cell lymphoma that was difficult to differentiate from metastatic pancreatic cancer and abdominal tuberculous lymphadenitis.
  • [MeSH-major] Lymphoma, Mantle-Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Tuberculosis, Lymph Node / diagnosis
  • [MeSH-minor] Abdomen / ultrasonography. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed


11. Tran H, Cheung C, Gill D, Dua U, Nourse J, Boyle R, Gandhi MK: Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nat Clin Pract Oncol; 2008 Apr;5(4):234-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis.
  • INVESTIGATIONS: Physical examination, blood tests, flow cytometry, fluorescent in situ hybridization, immunoglobulin gene sequencing, viral load quantification by real-time polymerase chain reaction, excisional lymph-node biopsy, bone-marrow biopsy, tumor morphology and immunohistochemistry, sequential CT and PET scans.
  • DIAGNOSIS: Methotrexate-associated mantle-cell lymphoma.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Lymphoma, Mantle-Cell / chemically induced. Methotrexate / adverse effects. Myasthenia Gravis / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lymphocytes. Lymphocytosis / chemically induced. Male. Risk Factors

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285762.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Pawarode A, Baer MR, Padmanabhan S, Wallace PK, Barcos M, Sait SN, Block AW, Wetzler M, Battiwalla M: Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. Leuk Lymphoma; 2005 Dec;46(12):1813-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature.
  • This paper reports a 73-year old woman with simultaneous presentation of acute monoblastic leukemia (acute myeloid leukemia (AML), French-American-British (FAB) type M5a) and mantle cell lymphoma.
  • Bone marrow and lymph node histopatholology showed extensive infiltration by leukemic monoblasts.
  • Flow cytometric immunophenotyping of peripheral blood, lymph node and bone marrow demonstrated two populations, expressing CD5, CD19, CD20 and CD22 and CD45, HLA-DR, CD13, CD33, CD14 and CD38, respectively.
  • A focus of abnormal lymphocytes in the lymph node biopsy demonstrated BCL1 expression and t(11;14)(p11;p13) by fluorescence in situ hybridization and immunoglobulin heavy chain gene rearrangement by the polymerase chain reaction.
  • The patient received infusional cytarabine, daunorubicin and etoposide chemotherapy, with complete remission of both the AML and the mantle cell leukemia.
  • To the authors' knowledge, this is the first report of simultaneous presentations of AML, FAB M5a and mantle cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Monocytic, Acute / complications. Lymphoma, Mantle-Cell / complications
  • [MeSH-minor] Aged. Antigens, CD / blood. Biopsy. Female. Humans. Lymphocytes / pathology. Treatment Outcome


13. Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R: Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol; 2006 Jun;209(2):250-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin class-switch recombination occurs in mantle cell lymphomas.
  • Mantle cell lymphoma (MCL) is an IgM-expressing B cell lymphoma that originates from naive B cells and responds poorly to chemotherapy.
  • Similar to the situation in normal B cells, in vitro stimulation of MCL cell lines with CD40 ligand (CD40L) and interleukin-4 induced expression of activation-induced cytidine deaminase (AID) and germline transcription at the immunoglobulin heavy chain gene locus.
  • Additionally, the occurrence of switch-circle transcripts and mature IgG transcripts after stimulation indicated ongoing class-switch recombination in mantle cell lymphoma cell lines.
  • Our data indicate that mantle cell lymphomas have retained the ability to undergo class-switch recombination if appropriate stimuli, such as the CD40 ligand, are provided.
  • [MeSH-major] Immunoglobulin Class Switching / genetics. Lymphoma, Mantle-Cell / genetics
  • [MeSH-minor] Antigens, CD40 / immunology. Cell Line, Tumor. Cytidine Deaminase / immunology. Dendritic Cells, Follicular / immunology. Genes, Immunoglobulin Heavy Chain / genetics. Genes, Immunoglobulin Heavy Chain / immunology. Humans. Immunoglobulin G / genetics. Immunoglobulin G / immunology. Immunohistochemistry / methods. Interleukin-4 / immunology. Mutation / genetics. Mutation / immunology. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Recombination, Genetic / genetics. Recombination, Genetic / immunology. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic / genetics. Transcription, Genetic / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16508921.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Immunoglobulin G; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 207137-56-2 / Interleukin-4; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


14. Yoshida K, Kayano H, Shimada T, Wakao D, Takahashi N, Sugahara Y, Yagasaki F, Ito Y, Kawai N, Matsuda A, Suzuki T, Bessho M: [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma]. Rinsho Ketsueki; 2003 Mar;44(3):174-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
  • Her white blood cell count was 25,510/microliters with 93% of lymphocytes.
  • Immunohistochemistry of a biopsied lymph node revealed that lymphoma cells were positive for cyclin D 1.
  • Mantle cell lymphoma (MCL) was diagnosed at clinical stage IV A.
  • Although a partial remission was obtained after CHOP plus rituximab therapy, the patient's disease recurred in March 2002 and she died in spite of salvage therapy including rituximab.
  • Immunohistochemistry of the bone marrow cells after salvage rituximab therapy revealed that lymphoma cells were still positive for CD 5 and cyclin D 1, but negative for CD 20 and sIgx.
  • We could not exactly determine how frequently CD 20 expression becomes negative in B-cell lymphomas after treatment with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / immunology. Cell Transformation, Neoplastic / drug effects. Cyclin D1 / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12722344.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 136601-57-5 / Cyclin D1; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


15. Potti A, Ganti AK, Kargas S, Koch M: Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res; 2002 Sep-Oct;22(5):2899-901
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
  • BACKGROUND: Mantle cell lymphoma (MCL) is a low-grade lymphoproliferative malignancy that is extremely refractory to chemotherapy.
  • Commonly used treatments have yielded unfavorable response rates (30% complete remission).
  • We evaluated the incidence of c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in patients with MCL in an effort to identify possible targets for therapeutic intervention.
  • MATERIALS AND METHODS: Patients with a diagnosis of MCL based on CD5 positivity associated with cyclin D1 positivity and CD23 negativity on the lymph node/bone marrow specimen were included in our retrospective study.
  • Although CD117 may not be of therapeutic significance, target-directed signal transduction inhibition therapy using VEGF-inhibitors may be a distinct possibility in a select group of patients with MCL.
  • [MeSH-major] Endothelial Growth Factors / biosynthesis. Intercellular Signaling Peptides and Proteins / biosynthesis. Lymphokines / biosynthesis. Lymphoma, Mantle-Cell / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12530014.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


16. Raderer M, Püspök A, Birkner T, Streubel B, Chott A: Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease. Leuk Lymphoma; 2004 Jul;45(7):1459-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease.
  • The stomach is the most common site of primary extranodal lymphoma.
  • Virtually all cases are of B-cell lineage, including extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) and diffuse large B-cell lymphomas.
  • While secondary gastric involvement from nodal mantle cell lymphoma (MCL) or in the course of primary intestinal MCL (lymphomatous polyposis) have been described, primary gastric MCL has not been reported so far.
  • A 74-year-old man with a 14 year-history of Crohn's disease was admitted at a general hospital due to epigastric pain refractory to therapy with proton-pump inhibitors.
  • Endosonography demonstrated the tumor to be limited to the stomach with only local lymph node involvement.
  • No further evidence of lymphoma was found on extensive clinical staging.
  • Following chemotherapy the patient is disease free at 24 months after diagnosis.
  • The lack of CD5 expression underscores the importance of performing thorough immunohistochemical studies, particularly to exclude MALT lymphoma.
  • [MeSH-major] Crohn Disease / complications. Lymphoma, Mantle-Cell / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Disease Susceptibility. Doxorubicin / administration & dosage. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / diagnosis. Male. Prednisone / administration & dosage. Remission Induction. Rituximab. Vincristine / administration & dosage


17. Valli VE, Vernau W, de Lorimier LP, Graham PS, Moore PF: Canine indolent nodular lymphoma. Vet Pathol; 2006 May;43(3):241-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine indolent nodular lymphoma.
  • B-Cell lymphomas (CD79a+) predominated.
  • Marginal zone lymphoma (MZL), the largest group, involved lymph node (33 cases) and spleen (13 cases), with both tissues involved in five of these cases.
  • Follicular lymphoma (FL) involved lymph nodes (five cases), and mantle cell lymphoma (MCL) occurred as solitary splenic masses (three cases).
  • Clonality status was determined in 54 cases by analysis of immunoglobulin heavy chain (IGH) and T-cell antigen receptor gamma (TCRG) gene rearrangement.
  • Limited survival data obtained for 18 dogs indicated that the B-cell lymphomas (MZL, MCL, and FL) and the T-cell lymphoma (TZL) were associated with indolent behavior and long survival.
  • [MeSH-major] Dog Diseases / diagnosis. Lymphoma, Follicular / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / veterinary. Male. Splenic Neoplasms / diagnosis. Splenic Neoplasms / drug therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672571.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C: Syk-dependent mTOR activation in follicular lymphoma cells. Blood; 2006 Dec 15;108(13):4156-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syk-dependent mTOR activation in follicular lymphoma cells.
  • The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy.
  • This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1.
  • Moreover, immunohistochemistry applied on lymph node tissue sections obtained from patients with FL revealed that, in most cases, p70S6 kinase was highly phosphorylated compared to normal tonsillar tissue.
  • Finally, Syk inhibition by piceatannol or by siRNA plasmids resulted in a potent inhibition of mTOR activity in FL cells, as well as in mantle cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma.
  • These findings suggest that the Syk-mTOR pathway has a critical function in FL survival, and therefore, that Syk could be a promising new target for B-lymphoma therapy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Lymphoma, Follicular / enzymology. Neoplasm Proteins / metabolism. Protein Kinases / metabolism. Protein-Tyrosine Kinases / metabolism. Signal Transduction
  • [MeSH-minor] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Burkitt Lymphoma / pathology. Cell Line, Tumor. Enzyme Activation / drug effects. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Mantle-Cell / pathology. Palatine Tonsil / enzymology. Palatine Tonsil / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Phospholipase D / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / pharmacology. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Stilbenes / pharmacology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912221.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Stilbenes; 4339-71-3 / 3,3',4,5'-tetrahydroxystilbene; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 3.1.4.4 / Phospholipase D
  •  go-up   go-down


19. Shvidel L, Sigler E, Shtalrid M, Feldberg E, Berrebi A: Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome. J Inherit Metab Dis; 2007 Oct;30(5):825
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome.
  • Increased risk of haematological malignancies has been described in Gaucher disease patients; however, high-grade lymphoma has been rarely observed.
  • We report two patients with Gaucher disease and sicca syndrome diagnosed with aggressive lymphoma involving the parotid gland.
  • A 29-year-old woman with Gaucher disease developed tumour of the left parotid gland.
  • Parotid gland biopsy disclosed diffuse large B-cell lymphoma.
  • MACOP-B chemotherapy regimen (cyclophosphamide, adriamycin, methotrexate, bleomycin, vincristine, prednisone) resulted in complete remission for 15 years.
  • He developed a left parotid gland tumour.
  • A cervical lymph node biopsy revealed mantle cell lymphoma.
  • Fine-needle aspiration of the parotid gland showed lymphoma cells.
  • Patients with Gaucher disease bear an increased risk of haematological malignancies; however, aggressive lymphoma has been described only occasionally.
  • In both our patients the presenting sign of lymphoma was tumour of the parotid gland.
  • The patients suffered from sicca syndrome, which increases risk for developing lymphoma.
  • The underlying Gaucher disease and sicca syndrome might be implicated as immunological triggers for lymphoma occurrence and its propensity for the parotid gland in these patients.
  • [MeSH-major] Gaucher Disease / complications. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis. Sjogren's Syndrome / complications
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / etiology. Male. Neoplasm Staging. Treatment Outcome


20. Mafune KI, Tanaka Y, Suda Y, Izumo T: Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification. Gastric Cancer; 2001;4(3):137-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification.
  • BACKGROUND: The best treatment for patients with non-Hodgkin's lymphoma (NHL) of the stomach is still uncertain.
  • The revised European-American lymphoma (REAL) classification has helped to define new, potentially more appropriate classification schemes for gastric lymphomas.
  • METHODS: Fifty-one resected gastric lymphomas were reclassified according to the REAL classification, and the efficacy of multimodal treatment was examined retrospectively.
  • The principal treatment plan consisted of:.
  • (1) surgical resection of the stomach with lymph node dissection, followed by (2) systemic chemotherapy, mainly using the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen.
  • Using the REAL classification, we diagnosed diffuse large B-cell lymphoma (DLBL) in 23 patients, marginal zone B-cell (low-grade mucosa-associated lymphoid tissue [MALT]-type) lymphoma in 22, follicle center lymphoma in 4, mantle cell lymphoma in 1, and peripheral T-cell lymphoma in 1 patient.
  • Univariate analysis indicated that the tumor histology (according to the REAL classification), depth of invasion, degree of nodal involvement, Ann Arbor staging, and chemotherapy had an impact on patient outcome (P = 0.0018; P = 0.0002; P = 0.0308; P = 0.0016, and P = 0.0118, respectively).
  • CONCLUSIONS: These data reveal that gastric NHL, especially of the low-grade MALT-type, often remains localized and has a good prognosis after surgery.
  • The REAL classification was useful for classifying new categories of NHL, including the MALT-type, in the clinical setting, and for determining the optimal treatment modality for gastric NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760079.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Ou J, Yang L, Ren L, Tang X, Li T, Wu S: [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma]. Zhonghua Nei Ke Za Zhi; 2002 Jan;41(1):28-30
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma].
  • OBJECTIVE: To deepen the understanding of splenic marginal zone lymphoma (SMZL) and improve the level of diagnosis and therapy.
  • Histologically, the neoplastic cells replaced the marginal and mantle zones with complete replacement of germinal centers in the white pulp.
  • Lymph nodes in the splenic hilum were infiltrated by tumor cells.
  • After splenectomy, COP chemotherapy and IFNalpha-2a were given and the abnormally increased lymphocytes decreased to normal level.
  • CONCLUSION: Splenomegaly, lymphocytosis in peripheral blood and bone marrow without lymph node enlargement and leukocytosis are clinical characters of SMZL.
  • Presence of monoclonal rearranged IgH gene is in favor of the diagnosis.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD20 / biosynthesis. Antigens, CD45 / biosynthesis. Cyclophosphamide / therapeutic use. Female. Gene Rearrangement. HLA-DR Antigens / biosynthesis. Humans. Immunoglobulin Heavy Chains / genetics. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Splenectomy. Splenomegaly / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11940293.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / HLA-DR Antigens; 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


22. Konuma T, Uchimaru K, Sekine R, Ohno N, Soda Y, Tomonari A, Ooi J, Nagamura F, Takahashi S, Iseki T, Oyaizu N, Tojo A, Asano S: Atypical hypersensitivity to mosquito bites without natural killer cell proliferative disease in an adult patient. Int J Hematol; 2005 Dec;82(5):441-4
MedlinePlus Health Information. consumer health - Mosquito Bites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical hypersensitivity to mosquito bites without natural killer cell proliferative disease in an adult patient.
  • Hypersensitivity to mosquito bites (HMB) is a rare disorder that occurs in the first 2 decades of life and is considered to be associated with chronic Epstein-Barr virus (EBV) infection and natural killer (NK) cell leukemia/lymphoma.
  • In this report, we present the case of an adult patient with mantle cell lymphoma complicated by atypical HMB.
  • The anti-EBV antibody titer of the patient indicated reactivation of chronic infection with this virus, and EBV DNA in the peripheral blood mononuclear cells was detected after chemotherapy by quantitative polymerase chain reaction analysis.
  • However, an in situ hybridization analysis did not detect EBER-positive cells in the skin lesion at the bite site or in the lymph node.
  • Peripheral NK cell lymphocytosis and EBV-associated lymphoproliferative disease did not develop.
  • These findings suggest that some patients with chronic EBV infection may develop HMB without NK cell proliferative disease.

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1997 Jan;88(1):82-7 [9045900.001]
  • [Cites] Jpn J Exp Med. 1982 Dec;52(6):303-6 [6133020.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):569-78 [11568749.001]
  • [Cites] Blood. 2001 Jul 15;98(2):280-6 [11435294.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):754-8 [15485536.001]
  • [Cites] Blood. 1965 Sep;26:257-68 [14332055.001]
  • [Cites] Eur J Dermatol. 2002 Jul-Aug;12(4):381-4 [12095889.001]
  • [Cites] J Infect Dis. 2001 Jan 1;183(1):1-7 [11106535.001]
  • [Cites] Intern Med. 2004 Oct;43(10):986-9 [15575253.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):223-8 [11039673.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1601-7 [14676078.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3173-4 [11721684.001]
  • [Cites] Arch Dermatol. 1999 Dec;135(12):1503-7 [10606056.001]
  • [Cites] Am J Hematol. 1997 Apr;54(4):276-81 [9092681.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):59-61 [15293569.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):259-62 [10846832.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2):124-32 [12704589.001]
  • (PMID = 16533749.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Vizer G, Bárány L, Baranyay F, Iványi JL: [Multiple lymphomatous polyposis--rare case of gastrointestinal hemorrhage]. Orv Hetil; 2001 May 20;142(20):1055-8
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computer tomography detected mesenterial, retroperitoneal and mediastinal lymph node involvement as well.
  • In this case the primary or secondary origin of the gastrointestinal lymphoma was not verifiable.
  • According to literature data this histological type of the gastrointestinal lymphoma has poor response to chemotherapy, the prognosis is unfavourable.
  • In this particular case the administered chemotherapy resulted in total remission at the lymphoma patient clinically staging III Ae.
  • In the proper follow-up examinations of the patient upper and lower endoscopy, histology samples, laboratory parameters, computer tomography, and physical examination in every 3 months are the methods.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Neoplasms / complications. Gastrointestinal Neoplasms / diagnosis. Lymphoma, Mantle-Cell / complications. Lymphoma, Mantle-Cell / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Colonic Polyps / complications. Colonic Polyps / diagnosis. Diagnosis, Differential. Duodenal Neoplasms / complications. Duodenal Neoplasms / diagnosis. Humans. Lymphatic Metastasis. Male. Middle Aged. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11407067.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement